These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 27150032)
1. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients. Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032 [TBL] [Abstract][Full Text] [Related]
2. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor. Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278 [TBL] [Abstract][Full Text] [Related]
3. Preparation of Guleria M; Amirdhanayagam J; Sarma HD; Rallapeta RP; Krishnamohan VS; Nimmagadda A; Ravi P; Patri S; Kalawat T; Das T Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436 [TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127 [TBL] [Abstract][Full Text] [Related]
5. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548 [TBL] [Abstract][Full Text] [Related]
6. Enhancing Treatment Efficacy of Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544 [TBL] [Abstract][Full Text] [Related]
8. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties. Hou H; Pan Y; Wang Y; Ma Y; Niu X; Sun S; Hou G; Tao W; Gao F Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2819-2832. PubMed ID: 38683349 [TBL] [Abstract][Full Text] [Related]
9. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298 [TBL] [Abstract][Full Text] [Related]
11. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Wang Z; Tian R; Niu G; Ma Y; Lang L; Szajek LP; Kiesewetter DO; Jacobson O; Chen X Bioconjug Chem; 2018 Sep; 29(9):3213-3221. PubMed ID: 30105912 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic Multidose Preparation of a Ready-to-Use Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687 [No Abstract] [Full Text] [Related]
13. Radiolabeling of PSMA-617 with Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216 [TBL] [Abstract][Full Text] [Related]
14. Results of a Prospective Phase 2 Pilot Trial of Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003 [TBL] [Abstract][Full Text] [Related]
15. Albumin-Binding and Conventional PSMA Ligands in Combination with Tschan VJ; Busslinger SD; Bernhardt P; Grundler PV; Zeevaart JR; Köster U; van der Meulen NP; Schibli R; Müller C J Nucl Med; 2023 Oct; 64(10):1625-1631. PubMed ID: 37442604 [TBL] [Abstract][Full Text] [Related]
16. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related]
17. Establishing Fendler WP; Stuparu AD; Evans-Axelsson S; Lückerath K; Wei L; Kim W; Poddar S; Said J; Radu CG; Eiber M; Czernin J; Slavik R; Herrmann K J Nucl Med; 2017 Nov; 58(11):1786-1792. PubMed ID: 28546332 [TBL] [Abstract][Full Text] [Related]
18. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178 [TBL] [Abstract][Full Text] [Related]
19. Value of post-therapy Tuncel M; Telli T Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750 [TBL] [Abstract][Full Text] [Related]